Compare Stocks: NVUS, PLUR, KALA, and NRSN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KALA KALA BIO	$0.95 +2.8%	$1.57	$0.59 ▼ $1,030.00	$17.87M	-2.26	93,983 shs	32,178 shs
NRSN NeuroSense Therapeutics	$0.45 +2.3%	$0.65	$0.39 ▼ $1.98	$16.73M	1.62	372,458 shs	55,308 shs
NVUS Novus Therapeutics	$3.13 +2.6%	$13.23	$4.50 ▼ $27.32	$4.50M	2.07	78,851 shs	1.36 million shs
PLUR Pluri	$1.59 -4.5%	$1.92	$1.45 ▼ $5.68	$17.93M	0.67	20,723 shs	2,989 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KALA KALA BIO	+2.81%	+27.04%	-7.77%	-67.58%	-99.76%
NRSN NeuroSense Therapeutics	+2.26%	-9.36%	-36.97%	-45.19%	-63.75%
NVUS Novus Therapeutics	0.00%	0.00%	0.00%	0.00%	+17.67%
PLUR Pluri	-3.23%	-13.75%	-9.31%	-52.91%	-66.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KALA KALA BIO	$0.95 +2.8%	$1.57	$0.59 ▼ $1,030.00	$17.87M	-2.26	93,983 shs	32,178 shs
NRSN NeuroSense Therapeutics	$0.45 +2.3%	$0.65	$0.39 ▼ $1.98	$16.73M	1.62	372,458 shs	55,308 shs
NVUS Novus Therapeutics	$3.13 +2.6%	$13.23	$4.50 ▼ $27.32	$4.50M	2.07	78,851 shs	1.36 million shs
PLUR Pluri	$1.59 -4.5%	$1.92	$1.45 ▼ $5.68	$17.93M	0.67	20,723 shs	2,989 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KALA KALA BIO	+2.81%	+27.04%	-7.77%	-67.58%	-99.76%
NRSN NeuroSense Therapeutics	+2.26%	-9.36%	-36.97%	-45.19%	-63.75%
NVUS Novus Therapeutics	0.00%	0.00%	0.00%	0.00%	+17.67%
PLUR Pluri	-3.23%	-13.75%	-9.31%	-52.91%	-66.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KALA KALA BIO	2.00	Hold	$1,158.33	121,829.82% Upside
NRSN NeuroSense Therapeutics	2.60	Moderate Buy	$8.50	1,775.97% Upside
NVUS Novus Therapeutics	0.00	N/A	N/A	N/A
PLUR Pluri	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVUS, PLUR, KALA, and NRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/11/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	NRSN NeuroSense Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/23/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	KALA KALA BIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/16/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/2/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/19/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KALA KALA BIO	N/A	N/A	N/A	N/A	$12.56 per share	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.05) per share	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	$13.13 per share	N/A
PLUR Pluri	$1.34M	12.78	N/A	N/A	($0.11) per share	-14.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KALA KALA BIO	-$26.98M	-$96.14	N/A	N/A	N/A	N/A	-1,336.10%	-94.85%	N/A
NRSN NeuroSense Therapeutics	-$11.12M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
NVUS Novus Therapeutics	-$16.01M	-$21.58	N/A	N/A	N/A	N/A	-133.49%	-30.52%	N/A
PLUR Pluri	-$22.58M	-$4.53	N/A	N/A	N/A	-2,162.08%	N/A	-106.59%	9/23/2026 (Estimated)

Latest NVUS, PLUR, KALA, and NRSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2026	Q1 2026	KALA KALA BIO	-$8.50	-$0.14	+$8.36	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KALA KALA BIO	N/A	7.91	7.91
NRSN NeuroSense Therapeutics	N/A	0.31	0.31
NVUS Novus Therapeutics	N/A	18.78	18.78
PLUR Pluri	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KALA KALA BIO	24.61%
NRSN NeuroSense Therapeutics	1.04%
NVUS Novus Therapeutics	N/A
PLUR Pluri	16.59%

Insider Ownership

Company	Insider Ownership
KALA KALA BIO	2.24%
NRSN NeuroSense Therapeutics	27.40%
NVUS Novus Therapeutics	2.20%
PLUR Pluri	43.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KALA KALA BIO	30	19.34 million	18.91 million	Not Optionable
NRSN NeuroSense Therapeutics	10	37.77 million	27.42 million	Not Optionable
NVUS Novus Therapeutics	7	1.44 million	N/A	Not Optionable
PLUR Pluri	150	10.79 million	6.13 million	No Data

NVUS, PLUR, KALA, and NRSN Headlines

Recent News About These Companies

Pluri’s Cellav Secures UK Cosmetic Registration for Regenativo+ Ahead of Regenerative Aesthetics Launch

July 28, 2026 | quiverquant.comQ

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

July 28, 2026 | globenewswire.com

Pluri in ongoing talks to extend EIB financing

July 17, 2026 | theglobeandmail.com

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

July 14, 2026 | markets.businessinsider.com

Pluri Receives Nasdaq Non-Compliance Notice, Faces Delisting Risk

July 13, 2026 | tipranks.com

Lab-grown coffee and chocolate could save both industries

June 26, 2026 | msn.com

Pluri Secures Insider Advance Subscription to Boost Liquidity

June 22, 2026 | tipranks.com

Plurilock Announces Results of Annual General Meeting

June 16, 2026 | newsfilecorp.comN

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

June 2, 2026 | globenewswire.com

Pluri in Good-Faith Talks on EIB Loan Resolution

June 1, 2026 | tipranks.com

Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In

May 31, 2026 | uk.finance.yahoo.com

Pluri Insider Ups Holding During Year

May 28, 2026 | finance.yahoo.com

Pluri Analyst Ratings and Price Targets | NASDAQ:PLUR | Benzinga

May 19, 2026 | benzinga.com

NewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth Plans

April 30, 2026 | quiverquant.comQ

Pluri Announces Financing Through Unregistered Equity Securities Deal

March 27, 2026 | tipranks.com

Pluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

March 26, 2026 | finanznachrichten.de

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

March 26, 2026 | finance.yahoo.com

Pluri Regains Nasdaq Compliance, Restoring Listing Stability

March 2, 2026 | tipranks.com

Pluri Biotech Secures China Patent for Immune Cell Tech

February 18, 2026 | contractpharma.comC

Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

February 18, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVUS, PLUR, KALA, and NRSN Company Descriptions

KALA BIO NASDAQ:KALA

$0.95 +0.03 (+2.81%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.90 -0.05 (-5.37%)

As of 08/14/2026 07:55 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

NeuroSense Therapeutics NASDAQ:NRSN

$0.45 +0.01 (+2.26%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.64%)

As of 08/14/2026 07:21 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Novus Therapeutics NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Pluri NASDAQ:PLUR

$1.59 -0.07 (-4.48%)

Closing price 08/14/2026 03:58 PM Eastern

Extended Trading

$1.62 +0.03 (+1.76%)

As of 08/14/2026 04:38 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVUS, PLUR, KALA, and NRSN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVUS, PLUR, KALA, and NRSN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVUS, PLUR, KALA, and NRSN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVUS, PLUR, KALA, and NRSN Company Descriptions

KALA BIO NASDAQ:KALA

NeuroSense Therapeutics NASDAQ:NRSN

Novus Therapeutics NASDAQ:NVUS

Pluri NASDAQ:PLUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVUS, PLUR, KALA, and NRSN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVUS, PLUR, KALA, and NRSN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVUS, PLUR, KALA, and NRSN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVUS, PLUR, KALA, and NRSN Company Descriptions

KALA BIO NASDAQ:KALA

NeuroSense Therapeutics NASDAQ:NRSN

Novus Therapeutics NASDAQ:NVUS

Pluri NASDAQ:PLUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools